NORDIC BIOTECH ADVISORS ApS: Financial statements 2012
CVR: 26123925
Source: annual report 2012, Danish Business Authority
01/01/2012 – 31/12/2012
NORDIC BIOTECH ADVISORS ApS (CVR 26123925) has filed annual accounts for 2012. In 2012, the company reported a gross profit of DKK 3,783,719 and a net result of DKK -62,812. Equity in the 2012 report amounted to DKK 1,365,485. The solvency ratio was 67.9%. The company had 2 employees in the financial year.
- Gross Profit
- DKK 3,783,719
- Profit/Loss
- DKK -62,812
- Equity
- DKK 1,365,485
- Total Assets
- DKK 2,010,791
- Employees
- 2
Official annual report
Keep an eye on NORDIC BIOTECH ADVISORS ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringAbout NORDIC BIOTECH ADVISORS ApS
NORDIC BIOTECH ADVISORS ApS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2001. The company is registered under the industry Andre aktiviteter i forbindelse med finansielle tjenesteydelser, undtagen forsikring og pensionsforsikring. The company was previously named NEXGEN BIOTECH ApS and NORDIC BIOTECH ApS. The management consists of Florian Schønharting. The board consists of Florian Schønharting and Jakob Mosegaard Larsen. The company is owned by TECH GROWTH INVEST ApS, C. HANSEN INVEST ApS and BVF/Nexgen Biotech, LP. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK 3,273,154 and a net result of DKK 360,368 compared with DKK -572,578 the year before. Equity in the 2025 report amounted to DKK 4,622,219.